

B'SYS GmbH

HEK TRPM8 Cell Line

Specification Sheet

© B'SYS GmbH

TABLE OF CONTENTS

1	BACKGROUND	3
1.1	The TRPM8 channel	3
1.2	B'SYS's HEK TRPM8 Cells	3
2	PRODUCT SHIPMENT	3
2.1	Product Format	3
2.2	Mycoplasma Certificate	3
3	VALIDATION OF HEK TRPM8 CELLS	4
3.1	Electrophysiology	4
3.2	Patch-clamp success rates	4
4	CELL CULTURE CONDITIONS	5
4.1	General	5
4.2	Recommended Complete Medium	5
4.3	Antibiotics	5
4.4	Thawing Cells	5
4.5	Splitting Cells	5
4.6	Freezing Medium	6
4.7	Freezing Cells	6
4.8	Stability of HEK TRPM8 cells	6
5	TRPM8 SEQUENCE	7
5.1	Human TRPM8 Accession Number NM_080704.2	7
6	CONTACT INFORMATION	9
6.1	Contact Address for Technical Support and Ordering Information	9

1 BACKGROUND

1.1 The TRPM8 channel

The transient receptor potential melastatin TRPM8 vanilloid receptor gates a Ca^{2+} permeable cation channel that is over expressed in prostate cancer and other malignancies. TRPM8 channels can be activated by cold and cooling compounds such as menthol and icilin (Bödding et al., 2007).

1.2 B'SYS's HEK TRPM8 Cells

B'SYS has designed a new HEK TRPM8 cell line with constitutive expression of human TRPM8 channel. The human TRPM8 cDNA was cloned and transfected into HEK T17/23 cells and then the functional properties of the TRPM8 channel was validated by means of the patch-clamp technique. The validation was made with menthol and cold stimulations. The TRPM8 antagonist SKF96365 was also used to block the channel at different concentrations depending on the stimulus used to activate the channel. Results are outlined in section 3.

2 PRODUCT SHIPMENT

2.1 Product Format

HEK cells stably transfected with recombinant human TRPM8 channel:

- 1x 0.5 mL aliquots of frozen cells at 2.4 E+06 cells/mL
- Cells are frozen in complete medium with 10% DMSO

2.2 Mycoplasma Certificate

B'SYS periodically tests cells for presence of mycoplasma by means of highly sensitive PCR based assays. All delivered cells are free of mycoplasma.

3 VALIDATION OF HEK TRPM8 CELLS

3.1 Electrophysiology

TRPM8 currents were measured by means of the patch-clamp technique in the whole-cell configuration. The bath solution contained (in mM) NaCl 137, KCl 4, CaCl₂ 1.8, MgCl₂ 1, Hepes 10, D-Glucose 10. The pH was adjusted to 7.4 with NaOH. The pipette solution consisted of (in mM) CsCl 145, NaCl 8, MgCl₂ 1, Mg-ATP 2, EGTA 5, Hepes 10. The pH was adjusted to 7.20 with CsOH. After formation of a GΩ seal between the patch electrodes and individual TRPM8 stably transfected HEK cells, the cell membrane across the pipette tip was ruptured to assure electrical access to the cell interior. As soon as a stable seal could be established the cells were clamped at -60 mV and the TRPM8 currents were activated by the application of different concentrations of menthol. TRPM8 currents elicited by 100 μM menthol were blocked by the agonist SKF96365 (1 μM) to control cell sensitivity.

3.2 Patch-clamp success rates

The patch-clamp properties of the HEK TRPM8 cell line were elucidated at typical working passage numbers (passage 22-26). A total of 16 cells were analyzed. Success for establishment of on-cell configuration was defined as follows: > 1 GΩ. The whole-cell configuration was not accepted if the membrane resistance was below 500 MΩ. A successful recording had to be free of rundown effects and variations in series resistance.

- On-cell successful: **94%** (n=15)
- Whole-cell successful: **94%** (n=15)
- Recording (15 min) successful: **75%** (n=12)




Fig.1: From top to bottom: Activation of TRPM8 currents by increasing concentrations of menthol (4 μM to 500 μM) / Dose response curve of menthol on TRPM8 current fitted to data from n=5 cells / Block of menthol-activated TRPM8 channels by 1 μM SKF-96365.

4 CELL CULTURE CONDITIONS

4.1 General

HEK TRPM8 cells are incubated at 37°C in a humidified atmosphere with 5% CO₂ (rel. humidity > 95%). The cells are continuously maintained and passaged in sterile culture flasks containing DMEM medium supplemented with 9% fetal bovine serum, 0.9% Penicillin/Streptomycin solution and 1 µg/mL Puromycin. The HEK TRPM8 cells are passaged at a confluence of about 80%. For electrophysiological measurements the cells are seeded onto e.g. 35 mm sterile culture dishes containing complete medium.

- All solutions and equipment coming in contact with the cells must be sterile.
- Use proper sterile technique and work in a laminar flow hood.
- Be sure to have frozen cell stocks at hand before starting experiments.
- Cells should be split every 2-3 days at 70% - 80% confluency at 1:3 to 1:5 ratio.

4.2 Recommended Complete Medium

- DMEM with GlutaMAX I
- 9% FBS
- 0.9% Penicillin/Streptomycin

4.3 Antibiotics

- HEK TRPM8 clones were selected under 1 µg/mL Puromycin antibiotic pressure.
- To cultivate HEK TRPM8 cells, also the same antibiotic pressure (1 µg/mL) can be used.
- To separate HEK TRPM8 cells from untransfected cells, use 1 µg/mL Puromycin

Remark: The permanent application of high antibiotic pressure has no effect on current density.

4.4 Thawing Cells

- Remove vial of cells from liquid nitrogen and thaw quickly at 37°C.
- Decontaminate outside of vial with 70% ethanol.
- Transfer cells to a T-75 culture flask containing 10 mL complete medium.
- Incubate cells at 37°C for 4-6 h to allow the cells to attach to the bottom of flask.
- Aspirate off the medium and replace with 10 mL complete medium & antibiotics.
- Antibiotics: 1 µg/mL Puromycin.
- Incubate cells and check them daily until 70% - 80% confluency is reached.

4.5 Splitting Cells

- When cells are 70% - 80% confluent remove medium.
- Wash cells once with 1x PBS to remove excess medium.
- Add 1x Trypsin/EDTA and incubate 30 s at room temperature.
- Remove Trypsin/EDTA quickly and incubate cells for 2 min at 37°C.
- Detach cells, add complete medium and pipet up and down to break clumps of cells.
- Passage cells into new flask with complete medium and antibiotics at 1:3 to 1:5 ratio.
- Add 2 µM SKF96365 blocker to the medium.

4.6 Freezing Medium

- Mix 0.9 mL fresh complete medium and 0.1 mL DMSO for every 1 mL freezing medium.
- Sterilize freezing medium by means of appropriate micro filter (0.1 µm – 0.2 µm).

4.7 Freezing Cells

- Prepare fresh freezing medium and keep it on ice.
- Cells should have 80% - 90% confluency prior to freezing.
- Remove the complete medium.
- Wash cells once with 1x PBS to remove excess medium.
- Add 1x Trypsin/EDTA and incubate 30 s at room temperature.
- Remove Trypsin/EDTA quickly and incubate cells for 2 min at 37°C.
- Detach cells, add complete medium and pipet up and down to break clumps of cells.
- Pellet cells with centrifuge and carefully aspirate off medium.
- Resuspend cells at a density of approximately 2.0 E+06 cells per mL with fresh freezing medium.
- Aliquot 0.5 mL of cell suspension into each cryovial.
- Overnight incubate cells in a styropor box at –80°C.
- The next morning transfer cryovial in liquid nitrogen tank for long-term storage.

4.8 Stability of HEK TRPM8 cells

HEK TRPM8 cells stably express functionally active TRPM8 channels over 35 passages. Under recommended cell culture conditions no variation in current density was observed over 35 cell splitting cycles.

5 TRPM8 SEQUENCE

5.1 Human TRPM8 Accession Number NM_080704.2

Cloned cDNA sequence of human TRPM8 subunit was error-free and identical with NM_024080.3 sequence:

```
atgatgtcctttcgggcagccaggctcagcatgaggaacagaaggaatgacactctggacagcaccgccgacctgtac
M M S F R A A R L S M R N R R N D T L D S T R T L Y
tccagcgcgtctcgggacacagacttgtccttacagtgaagcgacttgggaattttattcaagcaaattttaagaaa
S S A S R S T D L S Y S E S D L V N F I Q A N F K K
cgagaatgtgtccttcttatcaaagattccaaggccacggagaatgtgtgcaagtgtggctatgccagagccagcac
R E C V F F I K D S K A T E N V C K C G Y A Q S Q H
atggaaggcaccagatcaaccaaagtgagaaatggaactacaagaaacacaccaaggaatttcctaccgacgccttt
M E G T Q I N Q S E K W N Y K K H T K E F P T D A F
ggggatattcagtttgagacactggggaagaaaggaagtatatacgtctgtcctgacacggacgcggaaatcctt
G D I Q F E T L G K K G K Y I R L S C D T D A E I L
tacgagctgctgaccagcactggcacctgaaaacaccaacctggctcatttctgtgaccggggggcgaagaacttc
Y E L L T Q H W H L K T P N L V I S V T G G A K N F
gcctgaagccgcgcatgcaagatcttcagccggctcatctacatcgccagctcaaaggtgcttggattctcacg
A L K P R M R K I F S R L I Y I A Q S K G A W I L T
ggaggcaccattatggcctgatgaagtacatcggggaggtgggtgagagataacaccatcagcaggagttcagaggag
G G T H Y G L M K Y I G E V V R D N T I S R S S E E
aatattgtggccattggcatagcagcttggggcatggctccaaccgggacaccctcatcaggaattgcatgctgag
N I V A I G I A A W G M V S N R D T L I R N C D A E
ggctattttttagcccagcttcttgatgacttcacaagagatccactgtatatacctggacaacaaccacacacat
G Y F L A Q Y L M D D F T R D P L Y I L D N N H T H
ttgctgctcgtggacaatggctgtcagcactccctgtcgaagcaaagctccggaatcagctagagaagtatac
L L L V D N G C H G H P T V E A K L R N Q L E K Y I
tctgagcgcactattcaagattccaactatgggtggcaagatccccattgtgtgttttgccaaggaggtggaaaagag
S E R T I Q D S N Y G G K I P I V C F A Q G G G K E
actttgaaagccatcaatacctccatcaaaaataaaattccttgtgtgggtgggaaggctcgggcccagatcgctgat
T L K A I N T S I K N K I P C V V V E G S G Q I A D
gtgatcgctagcctgggtggaggtggaggatgcctgacatcttctgccgtcaaggagaagctgggtgcgctttttacc
V I A S L V E V E D A L T S S A V K E K L V R F L P
cgcacggtgtcccggctgctgaggaggagactgagagttggatcaaagctcaaagaaattctcgaatgttctcac
R T V S R L P E E E T E S W I K W L K E I L E C S H
ctataacagttatataaaatggaagaagctggggatgaaattgtgagcaatgccatctcctacgctctatacaaagcc
L L T V I K M E E A G D E I V S N A I S Y A L Y K A
ttcagcaccagtgagcaagacaaggataactggaatgggcagctgaagcttctgctggagtggaaaccagctggactta
F S T S E Q D K D N W N G Q L K L L L E W N Q L D L
gccaatgatgagattttaccaatgaccgcccagatgggagctgctgaccttcaagaagtcagtttacggctctcata
A N D E I F T N D R R W E S A D L Q E V M F T A L I
aaggacacccaagttgtccgctctttctggagaatggcttgaacctacggaagtttctcaccatgatgtcctc
K D R P K F V R L F L E N G L N L R K F L T H D V L
actgaactcttccaaccacttcagcacgcttgtgtaccggaatctgcagatcgccaagaattcctataatgatgcc
T E L F S N H F S T L V Y R N L Q I A K N S Y N D A
ctcctcacgtttctgctggaaactggttgcgaacttccgaagaggcttccggaaggaagacagaaatggccgggacgag
L L T F V W K L V A N F R R G F R K E D R N G R D E
atggacatagaactccacgacgtgtctcctattactcggcacccttgcaagctctcttcatctgggccattcttcag
M D I E L H D V S P I T R H P L Q A L F I W A I L Q
aataagaaggaactctcaaagtcatttgggagcagaccaggggctgcactctggcagccctgggagccagcaagctt
N K K E L S K V I W E Q T R G C T L A A L G A S K L
ctgaagactctggccaaagtgaagaacgacatcaatgctgctggggagtcgaggagctggctaagtgagtacgagacc
L K T L A K V K N D I N A A G E S E E L A N E Y E T
cgggctgtgagctgttactgagtggttacagcagcgatgaagacttggcagaacagctgctgggtctattcctgtgaa
R A V E L F T E C Y S S D E D L A E Q L L V Y S C E
```

gacttggcagaacagctgctgggtctattcctgtgaagcttgggggtggaagcaactgtctggagctggcgggtggaggcc
D L A E Q L L V Y S C E A W G G S N C L E L A V E A
acagaccagcatttcatcgcccagcctgggggtccagaattttctttctaagcaatgggatggagagatttccccgagac
T D Q H F I A Q P G V Q N F L S K Q W Y G E I S R D
accaagaactggaagattatcctgtgtctgtttattatacccttgggtgggctgtggcctttgtatcatttaggaagaaa
T K N W K I I L C L F I I P L V G C G F V S F R K K
cctgtcgacaagcacaagaagctgctttggactatgtggcgcttcttcacctcccccttctggtgcttctcctggaat
P V D K H K K L L W Y Y V A F F T S P F V V F S W N
gtggctcttctacatcgcttctcctgctgtttgcctacgtgctgctcatggatttccattcggtgccacacaccccc
V V F Y I A F L L L F A Y V L L M D F H S V P H P P
gagctggctcctgtactcgctgggtctttgtcctcttctgtgatgaagtgagacagtggtacgtaaattgggggtgaattat
E L V L Y S L V F V L F C D E V R Q W Y V N G V N Y
tttactgacctgtggaatgtgatggacacgctggggcttttttacttcatagcaggaattgtatttccggctccactct
F T D L W N V M D T L G L F Y F I A G I V F R L H S
tctaataaaagctctttgtattctggacgagtcattttctgtctggactacattattttctcactctaagattgatccac
S N K S S L Y S G R V I F C L D Y I I F T L R L I H
atttttactgtaagcagaaacttaggaccaagattataatgctgcagaggatgctgatcgatgtgttcttcttctcctg
I F T V S R N L G P K I I M L Q R M L I D V F F F L
ttcctctttgcgggtgtggatgggtggcctttggcgtggccaggcaagggatccttaggcagaatgagcagcgtggagg
F L F A V W M V A F G V A R Q G I L R Q N E Q R W R
tggatattccggttcggtcatctacgagccctacctggccatgttcggccaggtgccagtgacgtggatggtaccacg
W I F R S V I Y E P Y L A M F G Q V P S D V D G T T
tatgactttgcccactgcaccttactgggaatgagtccaagccactgtgtgtggagctggatgagcacaacctgccc
Y D F A H C T F T G N E S K P L C V E L D E H N L P
cggttccccgagtggatcaccatccccctgggtgtgcatctacatggtatccaccaacatcctgctgggtcaacctgctg
R F P E W I T I P L V C I Y M L S T N I L L V N L L
gtcgccatgtttggctacacgggtgggcaccgtccaggagaacaatgaccagggtctggaagttccagaggtacttctcctg
V A M F G Y T V G T V Q E N N D Q V W K F Q R Y F L
gtgcaggagtactgcagccgctcaatatcccccttcccccttcatcgcttctcgcttacttctacatgggtgggtgaagaag
V Q E Y C S R L N I P F P F I V F A Y F Y M V V K K
tgcttcaagtgttgctgcaaggagaaaaacatggagtcttctgtctgctgtttcaaaaatgaagacaatgagactctg
C F K C C C K E K N M E S S V C C F K N E D N E T L
gcatgggagggtgtcatgaaggaaaactaccttgtcaagatcaacacaaaagccaacgacacctcagaggaaatgagg
A W E G V M K E N Y L V K I N T K A N D T S E E M R
catcgatttagacaactggatacaaagcttaatgatctcaagggtcttctgaaagagattgctaa^{taa}
H R F R Q L D T K L N D L K G L L K E I A N -

6 CONTACT INFORMATION

6.1 Contact Address for Technical Support and Ordering Information

- B'SYS GmbH
Technology Center Witterswil
Benkenstrasse 254
4108 Witterswil
Switzerland

Tel: +41 61 721 77 44

Fax: +41 61 721 77 41

Email: info@bsys.ch

Web: www.bsys.ch